Terns Pharmaceuticals Inc... (TERN)
NASDAQ: TERN
· Real-Time Price · USD
7.07
0.30 (4.43%)
At close: Aug 15, 2025, 3:59 PM
7.12
0.78%
After-hours: Aug 15, 2025, 06:54 PM EDT
4.43% (1D)
| Bid | 7.04 |
| Market Cap | 618.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -91.75M |
| EPS (ttm) | -1.03 |
| PE Ratio (ttm) | -6.86 |
| Forward PE | -4.87 |
| Analyst | Buy |
| Ask | 7.18 |
| Volume | 1,613,151 |
| Avg. Volume (20D) | 940,287 |
| Open | 6.82 |
| Previous Close | 6.77 |
| Day's Range | 6.72 - 7.12 |
| 52-Week Range | 1.86 - 11.40 |
| Beta | -0.06 |
About TERN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TERN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TERN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-5.64%
TERN stock has given up its prior gain. Terns Phar...
Unlock content with
Pro Subscription
1 month ago
-5.64%
Terns Pharmaceuticals shares are trading higher after the company announced it will highlight data from the completed Phase 1 study of TERN-601 at the American Diabetes Association 85th Scientific Sessions. Also, the company completed enrollment for the Phase 2 FALCON trial.
1 week ago · fool.com
Terns (TERN) Q2 Net Loss Narrows 16%Terns (TERN) Q2 Net Loss Narrows 16%
1 month ago · seekingalpha.com
Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology CatalystsTerns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of best-in-c...
2 months ago · https://www.defenseworld.net
Squarepoint Ops LLC Has $73,000 Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Squarepoint Ops LLC cut its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report) by 75.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institu...